Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.
10h
Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee ...
Project Stargate will see companies like Oracle, SoftBank, MGX, and OpenAI commit an initial $100 billion to build data ...
Analysts on Wall Street project that Johnson & Johnson (JNJ) will announce quarterly earnings of $2 per share in its forthcoming report, representing a decline of 12.7% year over year.
Pharma giant Johnson & Johnson is buying Intra-Cellular Therapies, eying sales growth above analysts’ expectations through ...
5don MSN
House Speaker Mike Johnson revealed President Biden insisted to him he hadn’t issued an executive order freezing liquid ...
Wall Street indexes hit new highs, driven by optimism in tech stocks, following President Trump's announcement of a $500 ...
Johnson can keep the GOP united by proposing a bill ending every Democrat-supported malady at once.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback